Pricing Log in Create free account

Exelixis, Inc. (EXEL) vs Summit Therapeutics PLC (SMMT)

Exelixis, Inc. and Summit Therapeutics PLC are both Biotechnology companies. Exelixis, Inc. is the larger, with a market value of $15.6B against $12.3B — 1.3× the size. Summit Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Exelixis, Inc. trades at 18.8×. Exelixis, Inc. grew revenue faster over the last twelve months: 9.23% against −61.0%. Exelixis, Inc. has the higher net margin (35.3% vs 0.00%) and the higher return on invested capital (60.5% vs 0.00%). Across the 18 metrics below, Exelixis, Inc. leads on 16 and Summit Therapeutics PLC on 2.

Valuation

Metric EXEL SMMT Biotechnology median
P/E 18.82 n/m 8.50
P/S 6.40 16,148.72 9.71
P/B 8.45 18.07 2.13
Price to free cash flow 13.45 n/m 20.82
EV/EBITDA 14.76 n/m 0.64
EV/Sales 6.06 15,310.43 9.21
Earnings yield 5.31% (7.66%) (33.15%)
Free cash flow yield 7.43% (4.04%) (25.50%)

Profitability

Metric EXEL SMMT Biotechnology median
Gross margin 96.48% 100.00% 65.16%
Operating margin 39.88% 0.00% 0.00%
Net margin 35.33% 0.00% 0.00%
Free cash flow margin 47.55% 0.00% 0.00%
Return on equity 44.39% (192.50%) (56.36%)
Return on assets 33.28% (159.09%) (48.04%)
Return on invested capital 60.45% 0.00% 0.00%

Growth

Metric EXEL SMMT Biotechnology median
Revenue growth (TTM) 9.23% (61.03%) 6.02%
EPS growth (last fiscal year) 57.95% (364.52%) 30.26%
Revenue growth, 5-year CAGR 18.63% (46.49%) 9.41%
Net income growth, 5-year CAGR 47.58% 0.00% 0.00%

Health

Metric EXEL SMMT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.46 6.96 4.72
Net debt to EBITDA (1.18) 0.65 0.96

Dividend

Metric EXEL SMMT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric EXEL SMMT Biotechnology median
Market cap 15.57b 12.26b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack